Liver‐Targeted Toll‐Like Receptor 7 Agonist Combined With Entecavir Promotes a Functional Cure in the Woodchuck Model of Hepatitis B Virus
Kyle E. Korolowizc, Bin Li, Xu Huang, Changsuek Yon, Evelyn Rodrigo, Manny Corpuz, David M. Plouffe, Bhaskar V. Kallakury, Manasa Suresh, Tom Y.‐H. Wu, Andrew T. Miller, Stephan Menne – 8 July 2019 – Current therapeutics for chronic infection with hepatitis B virus (HBV) rarely induce functional cure due to the immunotolerant status of patients. Small molecule agonists targeting toll‐like receptor 7 (TLR7) have been shown to elicit a functional cure in animal models of HBV but sometimes with poor tolerability due to immune‐related toxicities.